QS Research · Michael Burry's Scion Capital analyst template · 2006
HUMANA INC (HUM)
As of 2026-11-18 · 12/15 boxes filled from SEC filings and market data
Report price $385.78 (close 2026-11-18); latest close $390.00 (2026-11-20), +1.1% since the report; figures re-marked at the latest close
Conclusion: PASS
Conviction low · base case none · downside -39% · upside +19%
At $385.78 the market pays 30.9x adjusted TTM earnings and 2.46x book for a 6.6% return on common equity, above the company's own 23.1x five-year median and above every profitable large peer. What is being priced is a margin recovery that management itself pushes into FY2026, with adjusted EPS guided to at least $9.50 against $17.14 in FY2025 on the Bonus Year 2026 Star Ratings headwind. PASS: the asymmetry does not pay. The downside is -38.2% to $238.30, on -25.0% earnings at a compressed P/E of 25.45x (today 30.9x). The upside is +20.0% to $462.94, on +20% earnings at today's P/E of 30.9x. That is a reward/risk of 0.52. There is no base case: no comparable peer multiple sets one, because the peers' P/E is GAAP and the company's GAAP P/E of 37.2x is more than 5% from the adjusted 30.9x the downside sits on, so a base at the peer multiple would rest on other earnings than either case. Conviction is low.
Key numbers
- Share price: $390.00
- Market cap: $46.84B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $154.19B
- P/E (TTM): 37.6x
- Price / book: 2.49x
- Earnings-quality flags (TTM): Impairments -$253.0M (20% of net income)
- P/E, adjusted (TTM): 31.2x
- Revenue growth (latest fiscal year): +10.1%
The 15 boxes
- ✓ 1. Long-form business notes
Humana is a government-payment health insurer: FY2025 premiums and services revenue of $129.66B (up from $77.16B in FY2020), 83% of it from federal contracts, with 96.3% of FY2025 premiums and services revenue ($123,842M) sitting in the Insurance segment and individual Medicare Advantage alone at $90,403M (70.3%). Membership has shifted and shrunk in count (15.0M medical members at 12/31/2025 versus ~17M at 12/31/2020) while individual MA grew to 5,249.3K from 3,962.7K, keeping Florida at roughly 14% of consolidated revenue. Earnings went the other way: operating income fell from $4.99B (FY2020) to $2.70B (FY2025) and $2.38B (TTM to 9/30/2026) on nearly double the revenue, with FY2025 net income $1.19B. As an insurer it is valued on earnings, book equity ($17.66B at 12/31/2025) and capital return, not enterprise value or EBITDA.
- ✓ 2. Competitive advantage
The sources describe no durable advantage: Humana competes in a highly competitive health benefits industry against other managed care companies, national insurers and HMOs/PPOs, many with larger membership and greater financial resources in its markets, and the 10-K states barriers to entry are not substantial and customers can switch plans relatively easily each Medicare Annual Enrollment Period. The financial record is consistent with weak pricing power: revenue rose from $77.16B (FY2020) to $129.66B (FY2025) and $154.19B (TTM to 2026-09-30) while operating income fell from $4.99B to $2.70B and $2.38B, and net income from $3.37B to $1.19B and $1.25B, over the same periods. The main quality lever, Medicare Advantage Star Ratings, deteriorated, and the models are shaped by CMS and state policy rather than by a moat.
- ✓ 3. 10-Q takeaways
Q3 2026 was a revenue-growth, margin-pressure quarter: total revenues rose 26.1% to $41.2 billion on Medicare membership growth, but the consolidated benefit ratio rose 280 bp to 93.9% and consolidated income from operations fell 81.3% to $75 million. GAAP EPS of $1.33 was flattered by a $358 million non-cash put/call valuation gain, leaving an Adjusted loss per share of $0.70 versus Adjusted EPS of $3.24 in Q3 2025. Management raised FY 2026 Adjusted EPS guidance to 'at least $9.50' from 'at least $9.00' and revised GAAP EPS guidance to 'at least $15.09' from 'at least $6.52'. Cash built to about $6.9 billion from $4.2 billion at December 31, 2025 on $5.4 billion of nine-month operating cash flow, helped by the $908 million MaxHealth acquisition and the new BlackRock primary-care joint venture.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.